Table 3.

Genotype frequencies of selected SNPs in pre-microRNAs among bladder cancer patients and controls and their association with bladder cancer risk

Genetic model	Genotype	Patients	Controls	Logistic regressiona
		n = 159 (%)	n = 298 (%)	OR (95 % CI)	P
mir-196a2 rs11614913 C/T
Codominant	T/T	52 (32.7 %)	76 (25.5 %)	1	0.015
	C/T	66 (41.5 %)	166 (55.7 %)	0.58 (0.37–0.92)
	C/C	41 (25.8 %)	56 (18.8 %)	1.08 (0.63–1.82)
Dominant	T/T	52 (32.7 %)	76 (25.5 %)	1	0.1
	C/T-C/C	107 (67.3 %)	222 (74.5 %)	0.70 (0.46–1.08)
Recessive	T/T-C/T	118 (74.2 %)	242 (81.2 %)	1	0.085
	C/C	41 (25.8 %)	56 (18.8 %)	1.49 (0.95–2.38)
Overdominant	T/T-C/C	93 (58.5 %)	132 (44.3 %)	1	0.004
	C/T	66 (41.5 %)	166 (55.7 %)	0.56 (0.38–0.83)
Log-additive	—	—	—	1.00 (0.76–1.32)	0.98
mir-499 rs3746444 G/A
Codominant	A/A	107 (67.3 %)	216 (72.5 %)	1	0.44
	G/A	45 (28.3 %)	68 (22.8 %)	1.33 (0.86–2.08)
	G/G	7 (4.4 %)	14 (4.7 %)	0.99 (0.39–2.53)
Dominant	A/A	107 (67.3 %)	216 (72.5 %)	1	0.25
	G/A-G/G	52 (32.7 %)	82 (27.5 %)	1.28 (0.84–1.96)
Recessive	A/A-G/A	152 (95.6 %)	284 (95.3 %)	1	0.89
	G/G	7 (4.4 %)	14 (4.7 %)	0.93 (0.37–2.38)
Overdominant	A/A-G/G	114 (71.7 %)	230 (77.2 %)	1	0.2
	G/A	45 (28.3 %)	68 (22.8 %)	1.33 (0.86–2.08)
Log-additive	—	—	—	0.86 (0.61–1.20)	0.38
mir146a rs2910164 C/G
Codominant	C/C	60 (37.7 %)	112 (37.6 %)	1	0.2
	C/G	73 (45.9 %)	154 (51.7 %)	0.88 (0.58–1.35)
	G/G	26 (16.4 %)	32 (10.7 %)	1.52 (0.83–2.78)
Dominant	C/C	60 (37.7 %)	112 (37.6 %)	1	0.97
	C/G-G/G	99 (62.3 %)	186 (62.4 %)	0.99(0.67–1.47)
Recessive	C/C-C/G	133 (83.7 %)	266 (89.3 %)	1	0.091
	G/G	26 (16.4 %)	32 (10.7 %)	1.61 (0.93–2.86)
Overdominant	C/C-G/G	86 (54.1 %)	144 (48.3 %)	1	0.24
	C/G	73 (45.9 %)	154 (51.7 %)	0.79 (0.54–1.16)
Log-additive	—	—	—	0.88 (0.66–1.18)	0.4

^aAdjusted by gender, age, smoking status, tumor stage, recurrence, and metastasis. Italicized values indicated a significant difference at the 5 % level

n number of individuals